About: Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada
Creator	Rotstein, Coleman Forbes, Leta Grant, Robert Knox, Jennifer Krzyzanowska, Monika Lee, Roy Liu, Geoffrey Ng, Pamela Vu, Kathy Warr, David
Source	Medline; PMC
abstract	PURPOSE: People with cancer face an elevated risk of infection and severe sequelae from COVID-19. Dexamethasone is commonly used for antiemetic prophylaxis with systemic therapy for cancer. However, dexamethasone is associated with increased risk of viral and respiratory infections, and causes lymphopenia, which is associated with worse outcomes during COVID-19 infections. Our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumors during the COVID-19 pandemic, while maintaining control of nausea and emesis. METHODS: We convened an expert panel to systematically review the literature and formulate consensus recommendations. RESULTS: No studies considered the impact of dexamethasone-based antiemetic regimens on the risk and severity of COVID-19 infection. Expert consensus recommended modifications to the 2019 Cancer Care Ontario Antiemetic Recommendations. CONCLUSION: Clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis. Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine. For regimens with low emetogenic risk, 5-HT(3) antagonists are recommended over dexamethasone.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1007/s00520-020-05588-6
bibo:pmid	32601854
has license	no-cc
sha1sum (hex)	af3bfab0f2e6388a61fd2bed43eeb3d106d77e62
schema:url	https://doi.org/10.1007/s00520-020-05588-6
resource representing a document's title	Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada
has PubMed Central identifier	PMC7324309
has PubMed identifier	32601854
schema:publication	Support Care Cancer
resource representing a document's body	covid:af3bfab0f2e6388a61fd2bed43eeb3d106d77e62#body_text
is schema:about of	named entity 'RISK OF' named entity 'antiemetic' named entity 'lymphopenia' named entity 'prophylaxis' named entity 'COVID-19' named entity 'risk' named entity 'elevated' named entity 'severe' named entity 'antiemetic' named entity 'antiemetic' named entity 'COVID' named entity 'respiratory infections' named entity 'nausea' named entity 'systemic therapy' named entity 'systemic therapy' named entity 'emesis' named entity 'prophylaxis' named entity 'antiemetic' named entity 'viral infections' named entity 'toxicity' named entity 'chemotherapy' named entity 'prophylaxis' named entity 'olanzapine' named entity 'solid tumors' named entity 'evidence-based guidelines' named entity 'meta-analyses' named entity 'dexamethasone' named entity 'risk factors' named entity 'vomiting' named entity 'ondansetron' named entity 'SARS-COV-2' named entity 'dexamethasone' named entity 'infection' named entity 'PubMed' named entity 'emesis' named entity 'current literature' named entity 'respiratory failure' named entity 'ASCO' named entity 'intravenous' named entity 'COVID-19 pandemic' named entity 'chemotherapy' named entity 'medRxiv' named entity 'COVID-19' named entity 'dexamethasone' named entity 'COVID-19 pandemic' named entity 'University Health Network' named entity 'dexamethasone' named entity 'randomized controlled' named entity 'SARS' named entity 'peer-reviewed' named entity 'antiemetic' named entity 'irinotecan' named entity 'COVID-19' named entity 'nausea' named entity 'COVID-19 infection' named entity 'COVID-19' named entity 'adverse events' named entity 'COVID-19 pandemic' named entity 'dexamethasone' named entity 'glucocorticoids' named entity '5-HT' named entity 'CCO' named entity 'Eisai' named entity 'double-blinded' named entity 'antiemetic' named entity 'April 15' named entity 'emetogenic' named entity 'systematic review' named entity 'gene transcription' named entity 'Antiemetic' named entity 'American Society for Clinical Oncology' named entity 'emetogenic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software